The Chemours Company (NYSE:CC - Get Free Report) reached a new 52-week low during trading on Tuesday after Barclays lowered their price target on the stock from $19.00 to $16.00. Barclays currently has an equal weight rating on the stock. Chemours traded as low as $12.96 and last traded at $12.94, with a volume of 150034 shares changing hands. The stock had previously closed at $13.53.
CC has been the subject of a number of other reports. Mizuho upgraded shares of Chemours from a "neutral" rating to an "outperform" rating and set a $19.00 price objective for the company in a research report on Thursday, March 27th. The Goldman Sachs Group cut their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a report on Tuesday, January 7th. BMO Capital Markets reduced their target price on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a report on Wednesday, February 19th. Morgan Stanley reduced their price target on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $25.00 price objective on shares of Chemours in a research report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $22.56.
View Our Latest Stock Analysis on CC
Institutional Investors Weigh In On Chemours
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CC. GAMMA Investing LLC increased its stake in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Chemours by 100.4% in the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in Chemours during the 4th quarter valued at about $48,000. Itau Unibanco Holding S.A. boosted its holdings in Chemours by 39.3% in the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after purchasing an additional 1,003 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Chemours in the fourth quarter worth $91,000. 76.26% of the stock is owned by hedge funds and other institutional investors.
Chemours Trading Up 0.9 %
The firm has a market capitalization of $1.95 billion, a P/E ratio of 22.95 and a beta of 1.84. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The stock has a 50 day simple moving average of $16.02 and a 200-day simple moving average of $18.11.
Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.37 billion. On average, equities research analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a dividend of $0.25 per share. The ex-dividend date was Friday, February 28th. This represents a $1.00 dividend on an annualized basis and a yield of 7.65%. Chemours's dividend payout ratio is presently 175.44%.
Chemours Company Profile
(
Get Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
